News

Colleen DeSimone has more than 25 years of strategic financial and operational experience in the biotechnology and pharmaceutical industries. Most recently, she provided financial consulting services for Casma since its inception and for numerous early-stage biotechnology companies. Previously, Colleen served as vice president of finance and controller at Syros Pharmaceuticals. Colleen joined Syros from Takeda…

Sambad comes to us most recently from Nirogy Therapeutics where he led the biology team to execute IND enabling studies of Nirogy’s lead small molecule inhibitor. He also led studies that identified mechanism of action of Nirogy’s metabolic inhibitor in direct cancer cell killing and activation of antitumor immunity. Before joining Nirogy, Sambad did his…

Christina received her Bachelor’s degree from University of Massachusetts/Amherst in Microbiology. She has been in and out of small biotech companies for over a decade and a half. Most recently, she spent a little over a year at Faze Medicines, where she worked on the impact of condensates in an oncology setting. Before that, she…

Tori joined Auron Therapeutics in August, 2022. Prior to joining Auron “officially” she worked as an HR Benefits Consultant for Auron and Celsius Therapeutics. Tori has an extensive background of working with early stage biotechnology companies to support the development of their operations, Human Resources and administration. She has held positions at Agios Pharmaceutics and…

Maulasri (Mauli) joined Auron Therapeutics in September 2022 as Senior Scientist I, Translational Biology. Prior to joining Auron Therapeutics, Mauli was an HRI scientist at Roswell Park Comprehensive Cancer Center, where she was involved in understanding the role of Th2 immune responses as well as lipid mediators in solid tumors. Mauli’s first foray into cancer…

Before joining Auron Therapeutics, Sara was an Investigator in the Tumor Biology group at H3 Biomedicine, where she led three RAS/RAF/MAPK drug discovery programs and was a member of the Target Discovery Initiative team. At Sanofi in Cambridge, MA, she led a cross-functional postdoctoral project across the pharmacology, genomics, and bioinformatics teams to understand how…

Henry joined Auron in June 2022 as a computational biologist. Prior to Auron, Henry was a Principal Scientist of molecular discovery at BioMedicine Design Pfizer in Cambridge MA, where he supported antibody drug discovery and optimization across multiple portfolio programs. He played an active role in developing experimental and bioinformatic methods to profile antibody repertoires…

Kim Straley joined Auron Therapeutics in March of 2021. Kim has 20 years of industry experience in cell biology small molecule drug discovery from her time at Vertex Pharmaceuticals and Agios Pharmaceuticals. Her career has focused on developing cell-based assays for SAR exploration as well as detailed mechanistic studies, both of which significantly contributed to…